LHDX Lucira Health Inc.

Medical Device Company
2.13
-0.05  -2%
Previous Close 2.18
Open 2.18
52 Week Low 1.98
52 Week High 11.1
Market Cap $84,918,780
Shares 39,867,972
Float 17,218,484
Enterprise Value $-2,454,822
Volume 47,669
Av. Daily Volume 106,671
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022.

    Recent Highlights

    • Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 2021 net revenue
    • Recorded first-time net income of $13.1 million
    • Entered into a debt facility agreement up to $80 million with Silicon Valley Bank and Hercules Capital; drew down first tranche of $30 million
    • Submitted a request for Emergency Use Authorization…
    View Full Article
  2. EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) for its COVID-19 & Flu test. The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza. Lucira is seeking FDA authorization before this upcoming fall and winter, when SARS-CoV-2 and influenza viruses are likely to co-circulate.

    "We are very proud to have reached this important milestone toward introducing the first at-home COVID-19…

    View Full Article
  3. EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced that both its COVID-19 & Flu and COVID-19 molecular tests have received CE Mark for professional use, clearing both tests for sale and distribution throughout the European Union.

    The Lucira COVID-19 & Flu and COVID-19 tests are Nucleic Acid Amplification Tests (NAAT) with sensitivity and specificity comparable to lab-based PCR assays, miniaturized to run on a palm-sized device with no separate instrument or reader, producing results in 30 minutes. Lucira's COVID-19 test is currently available in the…

    View Full Article
  4. EMERYVILLE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET.

    Lucira's management is scheduled to present at the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.

    About Lucira Health
    Lucira is a medical technology company focused on the development and commercialization of transformative…

    View Full Article
View All Lucira Health Inc. News